QTERN FDA approval date

The FDA approved QTERN on 27 Feb 2017.

FDA approval date
27 Feb 2017

Drug identity has not yet been verified against registry records

Also recorded as DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2017-02-27DayQTERNFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA209091", "applicant_as_listed_by_fda": "ASTRAZENECA AB", "brand_names": ["QTERN"], "active_ingredients": ["DAPAGLIFLOZIN", "SAXAGLIPTIN HYDROCHLORIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20170227", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026